Exonate, an mRNA therapy company focused on retinal diseases, announced that in collaboration with Janssen Pharmaceuticals, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, the first patient has been dosed with Exonate’s lead compound, EXN 407, in a Phase Ib/II clinical trial of patient volunteers with centre-involved diabetic macular oedema.
February 2, 2021
· 3 min read